Abstract
Purpose of Review: The goal of this review is to summarize stool-based testing for colorectal cancer (CRC). The key questions answered in this review were the advantages and limitations of each available stool-based test for CRC and to examine their comparative efficacy. Recent Findings: Guaiac-based fecal occult blood testing (gFOBT) is no longer a relevant test for CRC screening. fecal immunochemical testing (FIT) tests, especially quantitative assays, are clearly a reliable stool-based test. Multitarget DNA (mtsDNA) stool testing may represent a viable option as well, although cost and test characteristics are yet fully defined. Summary: FIT and mtsDNA represent the options for stool-based CRC screening. In larger screening centers, quantitative FIT assays represent an attractive option for stool-based testing. Qualitative FIT has applicability in smaller centers. Although a large validation trial showed promising results for mtsDNA, further head-to-head trials with FIT will help define the ultimate role of mtsDNA. Ultimately, however, the best test for CRC screening is the one performed stool-based CRC screening as an initial or alternative option can increase participation in CRC screening.
Original language | English (US) |
---|---|
Article number | 39 |
Journal | Current gastroenterology reports |
Volume | 19 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2017 |
Bibliographical note
Publisher Copyright:© 2017, Springer Science+Business Media, LLC.
Keywords
- Advanced adenoma
- Colorectal cancer
- Fit
- Screening
- gFOBT
- hsFOBT
- mtsDNA